1 Safe-Haven Stock for the Near Term

Behemoth biotech Gilead Sciences (NASDAQ: GILD) announced on March 2 that it will acquire up-and-coming cancer drug developer Forty Seven (NASDAQ: FTSV) for $4.9 billion. Biotech investors had been calling on Gilead to make strategic moves like this to shore up prospects in the wake of declining sales of its blockbuster hepatitis-C franchise. 

Image source: Getty Images.

Gilead made waves in 2017 when it announced an $11.9 billion agreement to buy Kite Pharma, a cell therapy specialist focused on immuno-oncology. With shuffling of management at Gilead over the past few years, investors have been watching for the new team to leave its mark. 

Continue reading

Source Fool.com